NASDAQ
31.49USD
0.00 (0.00%)
We have scored 24 news catalysts on Catalyst Pharmaceuticals, Inc. (CPRX) over the past 12 months. The biggest single-day move next to one of them came Mar 4, 2026, when CPRX closed +3.2%: “All You Need to Know About Catalyst (CPRX) Rating Upgrade to Strong Buy”. Coverage across the window leans positive (average ticker sentiment +0.42). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.9B
P/E
—
EPS
—
Beta
0.74
52W range
19.05-32.56
Day range
31.49–31.49
Open
31.49
Prev close
31.49
Volume
0
Avg volume
3M
Dividend
0.00
IPO
2006-11-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Catalyst Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CPRX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
